Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Item
http://www.wikidata.org/entity/Q31042601
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.Engagement in Care of High-Risk Hepatitis C Patients with Interferon-Free Direct-Acting Antiviral Therapies.Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non-medicare populations.Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States
P2860

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Item
http://www.wikidata.org/entity/Q31042601
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Disparate access to treatment ...... s: data from the TRIO network.
@ast
Disparate access to treatment ...... s: data from the TRIO network.
@en
type
label
Disparate access to treatment ...... s: data from the TRIO network.
@ast
Disparate access to treatment ...... s: data from the TRIO network.
@en
prefLabel
Disparate access to treatment ...... s: data from the TRIO network.
@ast
Disparate access to treatment ...... s: data from the TRIO network.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Disparate access to treatment ...... s: data from the TRIO network.
@en
P2093
P304
P31
P356
P433
P478
P577
P698
P921